The Hidden Cost of Fragmented Production: Why Your Supply Chain Model Is Lying to You

The vendor map in a typical medtech pitch deck is a model of efficiency: five clean boxes, four straight arrows, and a clear path to market. However, the financial reality of running that supply chain is often a chaotic mix of unscheduled holds, version-control discrepancies, and a quality team managing four separate audit calendars simultaneously.

For many growth-stage companies, the issue isn’t that they built the wrong supply chain; it’s that they built the right supply chain for the wrong scale. At clinical volumes, fragmentation is a manageable nuisance. At commercial scale, it becomes a financial and operational drain that the original model rarely accounts for. The goal is to make these hidden costs visible before they manifest as margin-eroding surprises.

The Supply Chain the Model Sees vs. The One That Runs

Most financial models begin and end with the Bill of Materials (BoM). While the BoM is a critical baseline, it consistently underestimates the true cost of production in a fragmented chain. [S1]

Growth-stage companies often treat manufacturing overhead as a roughly proportional percentage of the BoM. This assumption breaks down at commercial volumes, where the non-BoM costs of quality documentation, inspection, and supplier coordination compound. An industry rule of thumb suggests that doubling the assembly labor cost is a starting point to account for overhead, but for high-complexity medical devices spread across multiple specialized vendors, even that multiplier often falls short.

The financial model usually captures the cost of the parts; it rarely captures the coordination infrastructure required to synchronize four separate vendors and ensure they deliver a compliant device on a single schedule. [S2]

Mapping the Fragmented Chain: The Reality of Handoffs

In a multi-vendor production model, each handoff between organizations introduces a new layer of cost and risk. To understand the financial impact, one must look at what happens at the seams of the production map.

Production Step	The Handoff Reality	The Cost/Risk Implication
Injection Molder	Components are molded, inspected, and shipped to an external assembler.	Spec versions must match the assembler’s criteria perfectly. Any discrepancy leads to shipment delays or line holds.
Contract Assembler	Receives components and performs mechanical/electromechanical assembly.	Issues a separate batch record. Component lots may not be immediately traceable to the molder’s records.
Chemistry Processor	Performs specialized fills or lyophilization on partially assembled devices.	Environment control gaps exist during transport. Each handoff creates a contamination risk window.
Kitter / Packager	Receives finished components from multiple sources for final assembly and labeling.	Must manage label version control across four upstream quality systems. A single labeling error triggers a recall.
Internal QA Team	Reconciles documentation from all vendors to prepare the Device History Record (DHR)	Acts as an “integration layer” for four different systems. A single documentation gap blocks the entire lot release.

As noted by the Georgia Manufacturing Extension Partnership (GaMEP), production partners often change as volume milestones are met, adding logistical and documentation complexity at every transition. [S1]

The Four Hidden Costs the BoM Misses

There are four specific cost categories that rarely appear in the initial financial model but consistently impact the bottom line in fragmented models.

1. Coordination Overhead: Synchronizing four vendors requires significant management time. Scheduling calls, performing incoming inspections at every stage, and maintaining version-controlled specs across multiple quality systems are real labor costs that grow nonlinearly with volume.
2. The “Hidden Factory” of Documentation: This concept refers to the additional activities caused by poor quality control or system fragmentation. In a multi-vendor chain, the QA team must reconcile disparate batch records and lot data. Even with high product quality, a single missing document from one vendor can hold up an entire lot release.
3. Chain-of-Custody Risk Windows: Every physical transfer between vendors represents a risk to component integrity. Managing environment controls and cold chain requirements across organizations is significantly harder than maintaining them within an integrated system.
4. Secondary Markups and Misalignment: Each vendor in the chain requires their own margin. Furthermore, schedule misalignments between vendors generate carrying costs, line holds, or expediting fees that are often distributed across multiple invoices, making them harder to track as a single systemic issue.

Audit and Recall Exposure

Beyond direct costs, fragmentation introduces significant regulatory risk. Medical device recalls reached a four-year high in 2024, with Class I recalls hitting a 15-year peak. While fragmentation does not inherently cause recalls, it makes failure modes—such as parts-related or labeling issues—harder to detect and contain. Supply chain-related failures affected tens of millions of recalled units in 2024. [S3]

Furthermore, FDA enforcement intensity for medical device manufacturers increased materially in 2024 [S3]. Recent guidance suggests that FDA investigators have increasingly traced deficiencies back to the sponsor’s failure to monitor or intervene in CMO operations, particularly when quality issues arise during scale-up. A fragmented chain multiplies the number of relationships requiring active oversight. During an audit, the pressure to assemble documentation from four separate systems increases the risk of a critical gap surfacing.

WHEN THE COSTS BECOME VISIBLE

These systemic costs rarely surface gradually; they tend to arrive in clusters, often during a scale-up sprint.

• The Lot Release Hold: A documentation gap from a secondary vendor delays a commercial launch by weeks. The resulting carrying costs and lost revenue often dwarf the annual cost of the documentation process itself.
• The Inconsistent Audit: A pre-approval inspection reveals that lot traceability is inconsistent across vendors, requiring an emergency remediation effort to pull data from four separate quality systems.
• The COGS Variance: A year into commercial production, the CFO discovers that coordination overhead—inspections, deviations, and vendor management time—is significantly higher than the original model assumed.

The Case for Consolidated Production

The logical response to the costs of fragmentation is the shift toward a consolidated production architecture. By moving from a multi-vendor web to a vertically integrated partner, a medtech company essentially collapses the “handoff risk” entirely.

The advantages of this consolidated approach are both operational and financial:

• Unified Quality Management: Instead of reconciling four different batch records, the team works within a single Quality Management System (QMS). This reduces the documentation burden and streamlines the path to lot release.
• Real-Time DFM Feedback: When the people molding the parts sit in the same building as the people building the assembly lines, Design for Manufacturability (DFM) happens in real-time. This eliminates the “over the wall” communication gaps that lead to expensive tooling modifications.
• Closed-Loop Traceability: In an integrated environment, traceability is inherent. A single organization manages the component lot through assembly and packaging, dramatically reducing the risk of data gaps during an FDA audit.

Consolidation isn’t just about reducing the number of invoices; it’s about reducing the number of variables that can break a scale-up.

Building the Full Picture

The most effective way to address fragmentation is to account for it in the original production model. Approximately 75% of ventures fail to generate a return for investors in medtech [S1], often due to these overlooked operational hurdles. Take the time to map your current vendor chain. Count the handoffs, the incoming inspection steps, the separate quality systems, and the labor required to tie them together. That exercise usually produces a number that surprises even the most experienced operations leaders.

The cost is in the chain, not just the components. The question worth asking early is what the full picture actually adds up to.

About the Author

Jennifer Day is the Director of Customer Service, Project Management, & EHS at Tessy Plastics, where she leads the strategic coordination and delivery of high-volume medical device programs. With over 20 years of experience in manufacturing leadership, Jennifer specializes in navigating the complex transition from pilot validation to commercial scale-up by integrating cross-functional teams across engineering, quality, and environmental compliance. Her expertise in bridging the gap between customer requirements and operational execution helps medtech innovators mitigate the hidden costs of supply chain fragmentation while maintaining rigorous FDA and EHS standards.

Tessy is a private, family-owned organization; for over 50 years. Tessy’s heritage has empowered the company to provide stable, agile, and world-class global manufacturing solutions. Driven by a passion for seamless execution, Jennifer ensures that every project reflects the integrity and innovation of a global leader with a family-first heart.

Citations and Resources

[S1] Georgia Manufacturing Extension Partnership (GaMEP), Georgia Tech. ‘Scaling Up: What Does Designing for Manufacturability Mean and Why Does It Matter for New Medical Devices?’ May 2025. gamep.org/medical-device-design-manufacturing-at-scale/

[S2] SEACOMP. ‘The Importance of Traceability in Medical Device Manufacturing.’ seacomp.com/resources/importance-traceability-medical-device-manufacturing

[S3] Med Device Online. ‘The Hidden Costs of Multiple-Vendor Contract Manufacturing.’ meddeviceonline.com/doc/the-hidden-costs-of-multiple-vendor-contract-manufacturing-0001